Reading this on a mobile device? Try our optimized mobile version here: http://r.smartbrief.com/resp/edpHCfbwoceWALlpuKwD

  ADVERTISEMENT  
December 26, 2012News for the transfusion medicine and cellular therapy community

  Top Story 
 
  • Study links hepatitis C viral response to improved survival
    Patients with hepatitis C and advanced liver fibrosis who achieved sustained viral response for six months after treatment had a nearly four times lower risk of death from all causes than those whose viral load was not suppressed for at least six months. The rates of liver transplantation and liver failure were also significantly lower among those who had sustained viral response than those without it. The study, which involved 530 patients, appeared in the Journal of the American Medical Association. HealthDay News (12/25) LinkedInFacebookTwitterEmail this Story
  ADVERTISEMENT  
NEW Complement Coated C3 Control Cells!
Hemo bioscience has received FDA clearance for its complement coated control cells. Hemo bioscience C3 Control Cells can be used as a control to confirm the efficacy of the AHG reagent used during Direct and Indirect Anti-Globulin tests. For details regarding pricing, manufacturing schedule, and distribution channels email us or call 866-332-2835.

  Science & Health 
  • Analysis examines transfusion outcomes after myocardial infarction
    A meta-analysis of 10 studies linked blood transfusions in patients with acute myocardial infarction and anemia with an increased risk of death and subsequent MI. But limitations in the study mean doctors "should not use the results of this review to justify or limit the use of red blood cells," according to an accompanying editorial in the Archives of Internal Medicine. Researchers said more studies of the risks and benefits were needed. TheHeart.org (Montreal) (free registration) (12/25) LinkedInFacebookTwitterEmail this Story
 
  • Study: Vorinostat lowers GVHD risk after stem cell transplant
    Vorinostat, an FDA-approved treatment for cutaneous T-cell lymphoma, can lower the risk of graft-versus-host disease in patients undergoing allogeneic hematopoietic stem cell transplantation, according to a study presented at a hematology meeting. The researchers found that at day 100, grade 2-4 acute GVHD and severe grade 3-4 acute GVHD were lower among the patients given vorinostat compared with standard therapy. Transplant-related mortality at one year was also lower for vorinostat recipients, according to the study. Oncology Nurse Advisor online (12/25) LinkedInFacebookTwitterEmail this Story
  • Researchers develop "atlas" of human immune cells
    Researchers at Columbia University Medical Center in New York City have developed the first "atlas" of immune cells in the human body through a collaboration with the New York Organ Donor Network. Researchers studied deceased organ donors' tissues that are in direct contact with pathogens, such as spleen, lung, lymph, and small and large intestine tissues, according to a study published in the journal Immunity. The atlas is expected to improve understanding of T lymphocytes and aid in the development of methods for creating immunotherapies and vaccines. InfectionControlToday.com (12/25) LinkedInFacebookTwitterEmail this Story
  • Study provides insights into how herbal antimalarial works
    Halofuginone, a drug derived from the root of the blue evergreen hydrangea flowering plant, blocks the protein-assembly process that allows malaria parasites to live in the blood, according to a study published in the journal Nature. "Our new results solved a mystery that has puzzled people about the mechanism that has been used to treat fever from a malaria infection going back probably 2,000 years or more," said lead researcher Paul Schimmel of the Scripps Research Institute in California. Business Insider/Agence France-Presse (12/24) LinkedInFacebookTwitterEmail this Story
  ADVERTISEMENT  
Discount on Regenerative Medicine Journal offered to AABB members
AABB has partnered with Regenerative Medicine Journal to offer an online subscription for $30 per year to AABB members. This journal provides a forum to address the important challenges and advances in stem cell research and regenerative medicine. Visit the AABB Marketplace or add-on to your online AABB membership renewal.

  Emerging Trends 
  • Device performs blood tests for up to 50 biomarkers at once
    U.S. scientists have created and evaluated a microfluidic tool that has the ability to screen for as many as 50 biomarkers simultaneously using a drop of blood. The device, called the V-Chip, triggers reactions that move the dye up channels, with the distance traveled indicating the concentration of a substance in the blood. MedGadget.com (12/21) LinkedInFacebookTwitterEmail this Story
  Industry News & Practice 
  • Experimental drug shrinks tumors in blood cancer study
    The investigational drug belinostat achieved the primary goal of shrinking tumors in a Phase II trial involving patients with relapsed/refractory peripheral T-cell lymphoma who had not responded to at least one previous treatment. The treatment, which has fast-track and orphan-drug status, could be submitted for marketing approval by the middle of next year. Reuters (12/21) LinkedInFacebookTwitterEmail this Story
  Government & Regulatory 
  Association News 
  • Reminder: "Neonatal Transfusion Guidance" available in AABB Marketplace
    "Neonatal Transfusion Guidance" -- a digital download -- is available in the AABB Marketplace. The publication addresses the unique requirements for neonatal transfusion that affect processes and procedures in the continuum from collection and selection of blood components to the methods of administration. Other topics covered include the importance of communication among clinical staff, laboratory personnel and parents of neonates; component processing techniques such as irradiation, filtration and aliquoting; effects of component storage and preservation; and blood administration concerns (e.g., venous access, infusion pumps, blood warming). LinkedInFacebookTwitterEmail this Story
Learn more about AABB® ->Homepage  |  Join AABB  |  Conferences  |  Marketplace

Position TitleCompany NameLocation
Performance Improvement ConsultantBlood Systems, Inc.US - AZ - Scottsdale
Laboratory ManagerCreative Testing SolutionsUS - IL - Chicago
DIRECTOR, REGIONAL CENTER OPERATIONS IIUnited BloodUS - NV - Las Vegas
Quality SpecialistBlood Systems, Inc.US - NV - Las Vegas
Laboratory SupervisorCreative Testing SolutionsUS - IL - Chicago
LABORATORY MANAGERUnited Blood ServicesUS - NV - Las Vegas
DIRECTOR, COMMUNITY CENTER IUnited Blood ServicesUS - NV - Reno
QA SpecialistSan Diego Blood BankUS - CA
Reference TechnologistLifeStreamUS - CA - San Bernardino
West Coast Account ManagerMacopharma USAUS - Nationwide
Director, Patient Blood ManagementAABBUS - MD - Bethesda
Click here to view more job listings.

  SmartQuote 
Never get so fascinated by the extraordinary that you forget the ordinary."
--Magdalen Nabb,
British author


LinkedInFacebookTwitterEmail this Story

 
 
Subscriber Tools
     
Print friendly format | Web version | Search past news | Archive | Privacy policy

Advertise
Corporate Relations Manager:  Tamara Zein (240) 333-6604
Job Board: AABB CareerLink
 
Read more at SmartBrief.com
A powerful website for SmartBrief readers including:
 
 
 Recent AABB SmartBrief Issues:   Lead Editor:  Tom Parks
Managing Editor: Cristian Becker

Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
 
 
© 1999-2013 SmartBrief, Inc.® Legal Information